Literature DB >> 26806212

Cyclophosphamide in dermatology.

Janet Kim1, Jonathan J Chan1.   

Abstract

Cyclophosphamide is a chemotherapeutic agent which was first discovered in experimental tumours in rats, and it has since been widely used to treat malignancies and severe manifestations of various auto-immune diseases. High-dose chemotherapy and continuous daily oral regimens are associated with significant toxicity profiles, but i.v. pulsed regimens have lowered the rates of adverse effects in rheumatological studies. Cyclophosphamide has been shown to be useful in the treatment of severe autoimmune conditions due to its powerful immunosuppressive ability; however, it remains a relatively underused modality in dermatology. This article reviews the current literature on cyclophosphamide and its clinical applications in dermatology.
© 2016 The Australasian College of Dermatologists.

Entities:  

Keywords:  cutaneous; cyclophosphamide; dermatology; i.v.; pulsed; side-effect

Mesh:

Substances:

Year:  2016        PMID: 26806212     DOI: 10.1111/ajd.12406

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  12 in total

Review 1.  New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies.

Authors:  Oreste Lanza; Armando Ferrera; Simone Reale; Giorgio Solfanelli; Mattia Petrungaro; Giacomo Tini Melato; Massimo Volpe; Allegra Battistoni
Journal:  Med Sci (Basel)       Date:  2022-05-25

2.  The Effect of Acetylcysteine on Renal Function in Experimental Models of Cyclophosphamide-and Ifosfamide-Induced Cystitis.

Authors:  Lukasz Dobrek; Klaudia Nalik-Iwaniak; Kinga Fic; Zbigniew Arent
Journal:  Curr Urol       Date:  2020-10-13

3.  Whole-body Imaging of Cell Death Provides a Systemic, Minimally Invasive, Dynamic, and Near-real Time Indicator for Chemotherapeutic Drug Toxicity.

Authors:  Steven E Johnson; Andrey Ugolkov; Chad R Haney; Gennadiy Bondarenko; Lin Li; Emily A Waters; Raymond Bergan; Andy Tran; Thomas V O'Halloran; Andrew Mazar; Ming Zhao
Journal:  Clin Cancer Res       Date:  2018-11-12       Impact factor: 13.801

4.  Cloning, expression and identification of KTX-Sp4, a selective Kv1.3 peptidic blocker from Scorpiops pococki.

Authors:  Yan Zou; Feng Zhang; Yaxian Li; Yuanfang Wang; Yi Li; Zhengtao Long; Shujuan Shi; Li Shuai; Jiukai Liu; Zhiyong Di; Shijin Yin
Journal:  Cell Biosci       Date:  2017-11-06       Impact factor: 7.133

Review 5.  The Role of Antioxidants in Ameliorating Cyclophosphamide-Induced Cardiotoxicity.

Authors:  Muluken Altaye Ayza; Kaleab Alemayehu Zewdie; Bekalu Amare Tesfaye; Dawit Zewdu Wondafrash; Abera Hadgu Berhe
Journal:  Oxid Med Cell Longev       Date:  2020-05-10       Impact factor: 6.543

6.  Protective Effect of Croton macrostachyus (Euphorbiaceae) Stem Bark on Cyclophosphamide-Induced Nephrotoxicity in Rats.

Authors:  Muluken Altaye Ayza; Balasubramanian Rajkapoor; Dawit Zewdu Wondafrash; Abera Hadgu Berhe
Journal:  J Exp Pharmacol       Date:  2020-08-21

7.  CYP1B1 as a therapeutic target in cardio-oncology.

Authors:  Alexa N Carrera; Marianne K O Grant; Beshay N Zordoky
Journal:  Clin Sci (Lond)       Date:  2020-11-13       Impact factor: 6.124

Review 8.  Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases-Implications for Therapeutic Approaches.

Authors:  Tanja Fetter; Dennis Niebel; Christine Braegelmann; Joerg Wenzel
Journal:  Cells       Date:  2020-12-07       Impact factor: 6.600

Review 9.  Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.

Authors:  Luca Falzone; Salvatore Salomone; Massimo Libra
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

Review 10.  Systemic immunobiological, immunosuppressant, and oncologic agents for the treatment of dermatologic diseases during the SARS-CoV-2 (COVID-19) pandemic emergency: A quick review for a quick consultation.

Authors:  Giovanni Paolino; Santo Raffaele Mercuri; Pietro Bearzi; Carlo Mattozzi
Journal:  Dermatol Ther       Date:  2020-06-24       Impact factor: 3.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.